miR-216b Targets FGFR1 and Confers Sensitivity to Radiotherapy in Pancreatic Ductal Adenocarcinoma Patients Without EGFR or KRAS Mutation.


EGELİ Ü. , Tezcan G. , ÇEÇENER G. , TUNCA B. , Sevinc E. D. , KAYA E. , ...More

Pancreas, vol.45, no.9, pp.1294-302, 2016 (Journal Indexed in SCI Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 45 Issue: 9
  • Publication Date: 2016
  • Doi Number: 10.1097/mpa.0000000000000640
  • Title of Journal : Pancreas
  • Page Numbers: pp.1294-302
  • Keywords: pancreatic ductal adenocarcinoma, EGFR, KRAS, miR-216b, FGFR1, radiotherapy resistance, COLORECTAL-CANCER, GEMCITABINE, PROGRESSION, METASTASIS, INHIBITION, MICRORNAS, PROGNOSIS, CARCINOMA, INVASION, IMPACT

Abstract

Objectives: The success of gemcitabine plus radiotherapy is dependent on the mutation status of pancreatic ductal adenocarcinoma (PDAC) tumors in the EGFR and KRAS genes; however, radiotherapy resistance may also be modulated epigenetically by microRNA (miRNA) regulation. In this study, we examined the potential effect of miRNAs on the resistance to radiotherapy in cases without EGFR or KRAS mutation.